Scilex Holding CO 8-K filings

Scilex Holding Company announced that its Board of Directors has deferred the record date for its previously announced Series 1 Mandatory Exchangeable Preferred Stock dividend, with the new date to be determined at the Board's sole discretion.

Scilex Holding Company announced that its stockholders re-elected Jaisim Shah and Henry Ji, Ph.D. as Class III directors and ratified BPM LLP as its independent auditor for fiscal year 2025 at the reconvened 2025 Annual Meeting.

Scilex Holding Company has adjourned its 2025 Annual Meeting of Stockholders due to a lack of the required quorum, rescheduling the meeting for June 20, 2025, to allow more time for stockholder voting.

Scilex Holding Company amends its non-employee director compensation policy to reflect a 1-for-35 reverse stock split, adjusting equity grants accordingly.

Scilex Holding Company announced it has regained compliance with the Nasdaq minimum bid price requirement after maintaining a share price of $1.00 or greater for ten consecutive business days.

Scilex Holding Company has changed the record date for its previously announced dividend of preferred stock exchangeable for up to 10% of its ownership interest in Semnur Pharmaceuticals, Inc., from April 11, 2025, to May 2, 2025.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, amends its merger agreement with Denali Capital Acquisition Corp. to address Nasdaq delisting and extend key dates.

Scilex Holding Company enacted a 1-for-35 reverse stock split of its common stock, effective April 15, 2025, to meet Nasdaq's minimum bid price requirement.

Scilex Holding Company will implement a 1-for-35 reverse stock split, effective April 15, 2025, to meet Nasdaq's minimum bid price requirement.

Scilex Holding Company's stockholders approved a proposal to authorize a reverse stock split of the company's common stock at a ratio between 1-for-14 and 1-for-50.

Scilex Holding Company has changed the record date for its previously announced dividend of preferred stock exchangeable for up to 10% of its ownership interest in Semnur Pharmaceuticals, Inc.

Scilex Holding Company voluntarily terminated its Sales Agreement with B. Riley Securities Inc., Cantor Fitzgerald & Co., and H.C. Wainwright & Co., LLC, effective March 5, 2025.

Scilex Holding Company finalizes agreements for royalty rights and licensing to bolster financial position and global market reach.

Scilex Holding Company's subsidiary, Scilex Pharmaceuticals Inc., has granted RoyaltyVest Ltd. exclusive rights to develop and commercialize ZTlido and other lidocaine products outside of the United States and certain other territories.

Scilex Holding Company has extended the maturity date of its senior secured promissory note with Oramed Pharmaceuticals to December 31, 2025, in exchange for 3.25 million shares of common stock and other considerations.

Scilex Holding Company has regained compliance with Nasdaq listing rules after filing its delayed quarterly report for the period ended September 30, 2024.

Scilex Holding Company has deferred a significant debt payment by issuing 5 million shares and agreeing to a royalty on product sales.

Scilex Holding Company has announced a change to the record date for its previously announced dividend of preferred stock, moving it from November 7, 2024, to January 28, 2025.

Scilex Holding Company has successfully completed a registered direct offering, raising approximately $17 million through the sale of common stock, pre-funded warrants, and common warrants.

Scilex Holding Company has entered into a joint venture to develop and commercialize KDS2010, a novel oral tablet for obesity and neurodegenerative diseases, including Alzheimer's.

Scilex Holding Company has entered into agreements to sell up to 60,068,585 shares of its common stock held by SCLX Stock Acquisition JV to create a cash reserve and avoid potential defaults on its debt obligations.

Scilex Holding Company has appointed BPM LLP as its new independent registered public accounting firm, effective immediately, replacing its previous auditor.

David Lemus has resigned from the Scilex Holding Company Board of Directors, effective November 27, 2024, citing personal and professional reasons.

Scilex Holding Company has obtained waivers from its lenders, Oramed Pharmaceuticals and other institutional investors, to avoid default on its debt obligations due to a delay in filing its quarterly report.

Scilex Holding Company has received notices from Nasdaq regarding non-compliance with listing rules due to a late quarterly report filing and a low share price, potentially leading to delisting.

Scilex Holding Company has dismissed its auditor, Ernst & Young LLP, following a disagreement over the scope and timing of an investigation into certain contracts, leading to potential defaults on debt and a delay in filing its quarterly report.

Scilex Holding Co. has dismissed its auditor, Ernst & Young, due to an ongoing investigation into certain contracts, leading to a delay in its Q3 financial filing and potential Nasdaq delisting.

Scilex Holding Company received a notice from Nasdaq for failing to maintain a minimum share price of $1.00 for 30 consecutive days, placing its listing at risk.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, has announced the filing of a registration statement for its business combination with Denali Capital Acquisition Corp.

Scilex Holding Company declared a stock dividend of preferred shares exchangeable for a portion of its Semnur Pharmaceuticals subsidiary, contingent on the completion of Semnur's merger with Denali Capital Acquisition Corp.